SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: ARDM, BFRM, CRTX, MDT, Zogenix
MDT
|
|
|
+14.08%
in
118 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 260 entries as of 7/16/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pendin...
|
ETFI Health Innovators Index: Does R&D Lead to Higher Stock Prices?
MDT
|
|
|
-9.07%
in
245 days
(closed on 07/16/09)
<> 
<> The accompanying table includes statistics and the top five rated companies in the ETFI Global Health Innovators Index of companies with market caps over $100M which received FDA approval in the trailing 12-month period for either an original new drug or medical device product. The index includes companies which get approvals for drugs or biological agents classified as new chemical entities (i.e. excluding reformulations of existing drugs, generic drugs, and label extensions for existing produc...
|
Expanding Defensive Growth Index into Europe
MDT
|
|
|
-4.05%
in
20 days
(closed on 11/12/08)
<> 
<> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada.
Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie...
|
MDT is a HOLD
MDT
From the Blogosphere
BSX Settles, Lowers Results – Analyst Blog
|
|
|
Boston Scientific Corporation (BSX) settled its $296 million lawsuit with the U.S. Department of Justice (DOJ) related to product advisories issued by its Guidant subsidiary in 2005. The litigation pertained to alleged violations of the Food, Drug, and Cosmetic Act by Guidant. The allegations were reported prior to Boston’s acquisition of Guidant in 2006.
Boston has recorded the litigation expense in its third quarter of fiscal 2009 results and updated its income statement accordingly. The expense has lowered the company’s GAAP earnings per share by 19 cents into a loss per share of 6 cent< />< />< />< />< />< /><><><><><><><><>< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
SurModics Misses – Analyst Blog
|
|
|
SurModics’ (SRDX) fourth-quarter earnings per share came in at 18 cents, below the Zacks Consensus Estimate of 20 cents. The company reported revenues of $19.2 million, down 17% compared to the year ago period. In addition to quarterly results, SurModics came out with fiscal year 2009 results. The company recorded revenues of $121.5 million in 2009, up 25%, compared to $97 million in the previous year and earnings per share of $1.07 for 2009. <>On a business unit basis, apart from Diagnostic, revenues from the other three segments – Cardiovascular, Ophthalmology and Other Markets, recorded a<><><><><><><><><><><>< />< />< />< />< /><>< /><>< /><>< /><>< /><>< /><>< /><><>< /><>< /><>< />< />...
|
Analyst upgrades, downgrades and initiations: CMCSA, GAME, GRMN, ETN, FO, MDT, MSO ...
Dividend growth trio: Aflac, Medtronic and Colgate-Palmolive
MDT
+7.77%
in
7 days
Filed under: Newsletters, AFLAC Inc (AFL), Colgate-Palmolive (CL), Stocks to Buy  "One way to build an inflation hedge into your investment cash flows is to focus on stocks that are likely to boost their dividends on a regular basis," explains dividend specialist Chuck Carlson.
<>In his The DRIP Investor, which focuses on blue chip companies offering dividend reinvestment programs, he notes, "Since dividends are paid with cold cash, they can't be faked. Either you pay the dividend or you don't. They can't be some figment of accounting magic." Here, he looks at three favorite blue chips with stro...
|
ATS Medical Reports In-Line – Analyst Blog
|
|
|
ATS Medical, Inc. (ATSI) reported a third quarter 2009 net loss of 1 cent per share, in-line with the Zacks Consensus Estimate but better than the year-ago loss per share of 6 cents.
Total revenues for the reported quarter were $18.8 million, increasing 17.3% year over year. Excluding an unfavorable foreign currency translation (FX), total revenues increased 19.4% year over year. Growth was broad-based across its major business segments.
Heart valve therapy revenues increased 20.5% year over year to $14.2 million. In this segment, Mechanical valve revenues increased 10% year over year to $11....
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
Stock update and watch list 7/29/08
- Due to difficulties understanding the socialpicks system regarding changing rating from buy to hold and thus resetting the performance, I wanted to sum...
|
More Resources
|
About Medtronic Inc
- Answers.com
